Amplio Pharma AB 

Methotrexate Forte – an innovation towards its clinical proof of concept

OWNER

Marguerite Mensonides (See Profile)


Sector

Therapeutics

Stage

Development, market readiness, clinical trial

Country

SE


granted composition of matter patent (WO18/220101)

risk-reduced clinical development: capitalize on large quantity of known data

injectable drug product - large margins sales price and CoG

abbreviated clinical development program - fast track to MAA and launch

Status

Approved

IP Type

PCT

Time

14 years

Countries

Belgium
Denmark
Finland
France
Germany
Italy
Netherlands
Spain
Switzerland
USA
United Kingdom

Coverage

Claims

1. An immediate release pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, optionally in the association with one or more pharmaceutically acceptable excipient, carrier or diluent.

with dependent claims describing details on the formulation and its use in treatment of disease

Know more of this patent

View more

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 21st of February 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar